Reverse switching from the biosimilar SB2 to the originator infliximab in previously switched patients with inflammatory bowel diseases: results of a prospective long-term cohort study

Reverse switching from the biosimilar SB2 to the originator infliximab in previously switched patients with inflammatory bowel diseases: results of a prospective long-term cohort study

Background: Data regarding multiple switches including reverse switching between infliximab and its biosimilars are scarce in the field of inflammatory bowel diseases (IBD). Objectives: We investigated the clinical effectiveness as primary outcome measure after repeated switches. Secondary endpoints...

Full description

Saved in:
Bibliographic Details
Main Authors: Sarah Fischer, Moritz Donhauser, Sarah Cohnen, Konstantin Fietkau, Marcel Vetter, Maria Grübel-Liehr, Peter Dietrich, Timo Rath, Angelika Wilfer, Ludmilla Sologub, Sabine Krebs, Frank Dörje, Daniel Nagore, Sebastian Meyer, Markus F. Neurath, Raja Atreya
Format: Article
Language:English
Published: SAGE Publishing 2024-11-01
Series:Therapeutic Advances in Gastroenterology
Online Access:https://doi.org/10.1177/17562848241301887
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1177/17562848241301887

Similar Items